CD276 and neoplasm: FDA approved for aggressive lymphomas, it is being investigated as additive therapy for patients with recurrent medulloblastomas. This therapy uses the patient’s T cells and engineers them to produce chimeric antigen receptors on its surface to identify cancerous cells more efficiently. Therapy in participants of this trial begins after surgical resection, and the current expectation of this new trial is that the B7H3-specific CAR T cells will be able to directly interact with tumor cells due to the procedure using a catheter and may stimulate a positive response.